Corbus Pharmaceuticals Holdings, Inc. (CRBP)

$16.56

-0.2

(-1.19%)▲

Market is closed - opens 8 PM, 20 Nov 2024

Performance

  • $16.43
    $17.18
    $16.56
    downward going graph

    0.79%

    Downside

    Day's Volatility :4.34%

    Upside

    3.58%

    downward going graph
  • $4.00
    $61.90
    $16.56
    downward going graph

    75.85%

    Downside

    52 Weeks Volatility :93.54%

    Upside

    73.25%

    downward going graph

Returns

PeriodCorbus Pharmaceuticals Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-71.09%
-8.6%
0.0%
6 Months
-65.89%
-3.3%
0.0%
1 Year
260.0%
9.4%
0.0%
3 Years
-37.59%
6.2%
-24.5%

Highlights

Market Capitalization
204.1M
Book Value
$12.36
Earnings Per Share (EPS)
-4.75
PEG Ratio
0.0
Wall Street Target Price
59.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.82%
Return On Equity TTM
-51.32%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-16.1M
EBITDA
-45.6M
Diluted Eps TTM
-4.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.2
EPS Estimate Next Year
-5.47
EPS Estimate Current Quarter
-0.95
EPS Estimate Next Quarter
-1.02

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Corbus Pharmaceuticals Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 259.3%

Current $16.56
Target $59.50

Technicals Summary

Sell

Neutral

Buy

Corbus Pharmaceuticals Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
-6.28%
-65.89%
260.0%
-37.59%
-87.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.12%
-24.58%
-7.12%
15.69%
116.3%
Biontech Se
Biontech Se
-4.64%
15.06%
7.66%
-66.93%
422.85%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-19.77%
55.93%
41.76%
25.27%
116.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.29%
0.48%
25.55%
146.84%
108.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
NA
NA
0.0
-4.2
-0.51
-0.29
NA
12.36
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.02
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
Buy
$204.1M
-87.87%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
116.3%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
422.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
116.5%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
108.31%
32.84
-4.51%

Insights on Corbus Pharmaceuticals Holdings, Inc.

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 29.4% return, outperforming this stock by 70.2%

Institutional Holdings

  • Cormorant Asset Management, LLC

    16.63%

  • BlackRock Inc

    6.25%

  • Vanguard Group Inc

    5.30%

  • Morgan Stanley - Brokerage Accounts

    4.23%

  • Octagon Capital Advisors LP

    4.01%

  • State Street Corp

    3.63%

Company Information

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.

Organization
Corbus Pharmaceuticals Holdings, Inc.
Employees
19
CEO
Dr. Yuval Cohen Ph.D.
Industry
Health Technology

FAQs